Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)
The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine,...
Gespeichert in:
Veröffentlicht in: | Letters in applied microbiology 2019-11, Vol.69 (5), p.325-332 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 332 |
---|---|
container_issue | 5 |
container_start_page | 325 |
container_title | Letters in applied microbiology |
container_volume | 69 |
creator | Venema, K. Verhoeven, J. Verbruggen, S. Espinosa, L. Courau, S. |
description | The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine.
Significance and Impact of the Study
Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.
Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains. |
doi_str_mv | 10.1111/lam.13211 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6856813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352423827</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</originalsourceid><addsrcrecordid>eNqFks9qFTEUhwdR7G114QtIwE0LTpuTyWTmboRS_FO4RRcV3IXczJnelGRyTTIjd-cj9DF8Lp_E1KlFBTGbkJzvfOSEX1E8A3oMeZ1Y5Y6hYgAPigXwhpWNqD89LBaUCVG2rOZ7xX6M15TSFtjycbFXAa85Z_Wi-PYh-LXxyWgSxzCZSVnSjcEMV0QRN9pkvn-9sWqHATuS1NpiIh1OaP3W4ZCIiiRhTLlohtzR7QbljH5JtHfbMWHI3doPKXhrZ2Yy-UCc79AS35O0QRKTd0pviBo6Ep2yNnO3UjMgObw8v8gOOHpSPOqVjfj0bj8oPr55fXn2rly9f3t-droqNecAZQVLhrRvK05rqnjDO0ShAapeN7RHLtSSLrHt-66FhiqmRSdEvmLA170GVh0Ur2bvdlw77HQeMigrt8E4FXbSKyP_rAxmI6_8JEVbixaqLDi8EwT_ecxjSGeiRmvVgH6MklU146xqWfN_lLXQirpuIKMv_kKv_RiG_BNZSBsqspZn6mimdPAxBuzv3w1U3kZF5qjIn1HJ7PPfB70nf2UjAycz8MVY3P3bJFenF7PyB_-QzTg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307062354</pqid></control><display><type>article</type><title>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Venema, K. ; Verhoeven, J. ; Verbruggen, S. ; Espinosa, L. ; Courau, S.</creator><creatorcontrib>Venema, K. ; Verhoeven, J. ; Verbruggen, S. ; Espinosa, L. ; Courau, S.</creatorcontrib><description>The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine.
Significance and Impact of the Study
Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.
Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.</description><identifier>ISSN: 0266-8254</identifier><identifier>EISSN: 1472-765X</identifier><identifier>DOI: 10.1111/lam.13211</identifier><identifier>PMID: 31454425</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Adults ; Aged ; Bifidobacterium ; Bifidobacterium - growth & development ; Bifidobacterium bifidum ; Bifidobacterium longum ; cell viability ; coatings ; Computer simulation ; Drug Compounding ; elderly ; Gastrointestinal system ; Gastrointestinal tract ; Geriatrics ; Humans ; Impact prediction ; Intestine ; Intestine, Small - microbiology ; Lactobacillus ; Lactobacillus - growth & development ; Lactobacillus gasseri ; Microbial Viability ; multi‐layered tablet ; Optimization ; Original ; probiotic ; Probiotics ; Probiotics - chemistry ; Small intestine ; Stomach ; Stomach - microbiology ; Survival ; Tablets - chemistry ; TIM‐1 ; Transit ; Yogurt</subject><ispartof>Letters in applied microbiology, 2019-11, Vol.69 (5), p.325-332</ispartof><rights>2019 The Authors. published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology.</rights><rights>2019 The Authors. Letters in Applied Microbiology published by John Wiley & Sons Ltd on behalf of Society for Applied Microbiology.</rights><rights>Copyright © 2019 The Society for Applied Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</citedby><cites>FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</cites><orcidid>0000-0001-7046-5127</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Flam.13211$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Flam.13211$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31454425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Venema, K.</creatorcontrib><creatorcontrib>Verhoeven, J.</creatorcontrib><creatorcontrib>Verbruggen, S.</creatorcontrib><creatorcontrib>Espinosa, L.</creatorcontrib><creatorcontrib>Courau, S.</creatorcontrib><title>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</title><title>Letters in applied microbiology</title><addtitle>Lett Appl Microbiol</addtitle><description>The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine.
Significance and Impact of the Study
Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.
Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.</description><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Bifidobacterium</subject><subject>Bifidobacterium - growth & development</subject><subject>Bifidobacterium bifidum</subject><subject>Bifidobacterium longum</subject><subject>cell viability</subject><subject>coatings</subject><subject>Computer simulation</subject><subject>Drug Compounding</subject><subject>elderly</subject><subject>Gastrointestinal system</subject><subject>Gastrointestinal tract</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>Impact prediction</subject><subject>Intestine</subject><subject>Intestine, Small - microbiology</subject><subject>Lactobacillus</subject><subject>Lactobacillus - growth & development</subject><subject>Lactobacillus gasseri</subject><subject>Microbial Viability</subject><subject>multi‐layered tablet</subject><subject>Optimization</subject><subject>Original</subject><subject>probiotic</subject><subject>Probiotics</subject><subject>Probiotics - chemistry</subject><subject>Small intestine</subject><subject>Stomach</subject><subject>Stomach - microbiology</subject><subject>Survival</subject><subject>Tablets - chemistry</subject><subject>TIM‐1</subject><subject>Transit</subject><subject>Yogurt</subject><issn>0266-8254</issn><issn>1472-765X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqFks9qFTEUhwdR7G114QtIwE0LTpuTyWTmboRS_FO4RRcV3IXczJnelGRyTTIjd-cj9DF8Lp_E1KlFBTGbkJzvfOSEX1E8A3oMeZ1Y5Y6hYgAPigXwhpWNqD89LBaUCVG2rOZ7xX6M15TSFtjycbFXAa85Z_Wi-PYh-LXxyWgSxzCZSVnSjcEMV0QRN9pkvn-9sWqHATuS1NpiIh1OaP3W4ZCIiiRhTLlohtzR7QbljH5JtHfbMWHI3doPKXhrZ2Yy-UCc79AS35O0QRKTd0pviBo6Ep2yNnO3UjMgObw8v8gOOHpSPOqVjfj0bj8oPr55fXn2rly9f3t-droqNecAZQVLhrRvK05rqnjDO0ShAapeN7RHLtSSLrHt-66FhiqmRSdEvmLA170GVh0Ur2bvdlw77HQeMigrt8E4FXbSKyP_rAxmI6_8JEVbixaqLDi8EwT_ecxjSGeiRmvVgH6MklU146xqWfN_lLXQirpuIKMv_kKv_RiG_BNZSBsqspZn6mimdPAxBuzv3w1U3kZF5qjIn1HJ7PPfB70nf2UjAycz8MVY3P3bJFenF7PyB_-QzTg</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Venema, K.</creator><creator>Verhoeven, J.</creator><creator>Verbruggen, S.</creator><creator>Espinosa, L.</creator><creator>Courau, S.</creator><general>Oxford University Press</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7ST</scope><scope>7T7</scope><scope>7TM</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>SOI</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7046-5127</orcidid></search><sort><creationdate>201911</creationdate><title>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</title><author>Venema, K. ; Verhoeven, J. ; Verbruggen, S. ; Espinosa, L. ; Courau, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4411-3192e0f834050a474dee6c113fc70fe46a909e8ffd8170a2c6d66909214bfc123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Bifidobacterium</topic><topic>Bifidobacterium - growth & development</topic><topic>Bifidobacterium bifidum</topic><topic>Bifidobacterium longum</topic><topic>cell viability</topic><topic>coatings</topic><topic>Computer simulation</topic><topic>Drug Compounding</topic><topic>elderly</topic><topic>Gastrointestinal system</topic><topic>Gastrointestinal tract</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>Impact prediction</topic><topic>Intestine</topic><topic>Intestine, Small - microbiology</topic><topic>Lactobacillus</topic><topic>Lactobacillus - growth & development</topic><topic>Lactobacillus gasseri</topic><topic>Microbial Viability</topic><topic>multi‐layered tablet</topic><topic>Optimization</topic><topic>Original</topic><topic>probiotic</topic><topic>Probiotics</topic><topic>Probiotics - chemistry</topic><topic>Small intestine</topic><topic>Stomach</topic><topic>Stomach - microbiology</topic><topic>Survival</topic><topic>Tablets - chemistry</topic><topic>TIM‐1</topic><topic>Transit</topic><topic>Yogurt</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Venema, K.</creatorcontrib><creatorcontrib>Verhoeven, J.</creatorcontrib><creatorcontrib>Verbruggen, S.</creatorcontrib><creatorcontrib>Espinosa, L.</creatorcontrib><creatorcontrib>Courau, S.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Environment Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Letters in applied microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Venema, K.</au><au>Verhoeven, J.</au><au>Verbruggen, S.</au><au>Espinosa, L.</au><au>Courau, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1)</atitle><jtitle>Letters in applied microbiology</jtitle><addtitle>Lett Appl Microbiol</addtitle><date>2019-11</date><risdate>2019</risdate><volume>69</volume><issue>5</issue><spage>325</spage><epage>332</epage><pages>325-332</pages><issn>0266-8254</issn><eissn>1472-765X</eissn><abstract>The aim of the research was to develop a galenical formulation for the combination of the three probiotic strains Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3 and Bifidobacterium bifidum MF 20/5 that would lead to the presence of a high amount of viable cells in the small intestine, the presumed site of action of these strains. This was tested in a validated, dynamic in vitro model of the stomach and small intestine (TIM‐1), simulating human adults after intake of a meal. Experiments were performed both in the gastric compartment of the model, as well as in the complete system (stomach + small intestine). Survival of the strains in an unformulated probiotic powder after transit through the gastric compartment was 5·3% for the bifidobacteria and 1% for L. gasseri. After transit through the complete gastrointestinal tract, this dropped to 2% for bifidobacteria and 0·1% for Lactobacillus. After several rounds of optimization, an enteric‐coated tablet was developed that increased the delivery of viable cells reaching the small intestine to 72% (gastric survival) for bifidobacteria, and 53% (gastric) for L. gasseri. Also survival in the small intestine increased by about an order of magnitude. The final galenical formulation was tested in two applications: adults and elderly, both of which have their own physiological parameters. These experiments corroborated the results obtained in the development phase of the project. In conclusion, the developed enteric coating led to a 20‐ to 40‐fold increase in the delivery of viable cells to the small intestine.
Significance and Impact of the Study
Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.
Significance and Impact of the Study: Predictive GI in vitro models are very helpful and reliable tools for the development of new galenical formula containing probiotics, and in the current example helped to deliver >10‐fold higher numbers of viable cells to the small intestine, presumably leading to improved functionality of the strains.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31454425</pmid><doi>10.1111/lam.13211</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7046-5127</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0266-8254 |
ispartof | Letters in applied microbiology, 2019-11, Vol.69 (5), p.325-332 |
issn | 0266-8254 1472-765X |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6856813 |
source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Adult Adults Aged Bifidobacterium Bifidobacterium - growth & development Bifidobacterium bifidum Bifidobacterium longum cell viability coatings Computer simulation Drug Compounding elderly Gastrointestinal system Gastrointestinal tract Geriatrics Humans Impact prediction Intestine Intestine, Small - microbiology Lactobacillus Lactobacillus - growth & development Lactobacillus gasseri Microbial Viability multi‐layered tablet Optimization Original probiotic Probiotics Probiotics - chemistry Small intestine Stomach Stomach - microbiology Survival Tablets - chemistry TIM‐1 Transit Yogurt |
title | Probiotic survival during a multi‐layered tablet development as tested in a dynamic, computer‐controlled in vitro model of the stomach and small intestine (TIM‐1) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T10%3A33%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotic%20survival%20during%20a%20multi%E2%80%90layered%20tablet%20development%20as%20tested%20in%20a%20dynamic,%20computer%E2%80%90controlled%20in%20vitro%20model%20of%20the%20stomach%20and%20small%20intestine%20(TIM%E2%80%901)&rft.jtitle=Letters%20in%20applied%20microbiology&rft.au=Venema,%20K.&rft.date=2019-11&rft.volume=69&rft.issue=5&rft.spage=325&rft.epage=332&rft.pages=325-332&rft.issn=0266-8254&rft.eissn=1472-765X&rft_id=info:doi/10.1111/lam.13211&rft_dat=%3Cproquest_pubme%3E2352423827%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2307062354&rft_id=info:pmid/31454425&rfr_iscdi=true |